Gastroesophageal reflux after sleeve gastrectomy: The dimension of the problem.

Sleeve gastrectomy is a safe and effective bariatric surgery in terms of weight loss and longterm improvement or resolution of comorbidities. However, its achilles heel is the possible association with the development with the novo and/or worsening of pre-existing gastroesophageal reflux disease. The anatomical and mechanical changes that this technique induces in the esophagogastric junction, support or contradict this hypothesis. Questions such as «what is the natural history of gastroesophageal reflux in the patient undergoing gastric sleeve surgery?¼, «how many patients after vertical gastrectomy will develop gastroesophageal reflux?¼ and «how many patients will worsen their previous reflux after this technique?¼ are intended to be addressed in the present article.

Cirugía bariátrica: resultados clínicos en términos de pérdida de peso y resolución de comorbilidades / Bariatric surgery: Clinical outcomes in terms of weight loss and resolution of comorbidities

Introducción. La cirugía bariátrica es una estrategia válida de tratamiento en obesidad severa. El objetivo de este estudio fue evaluar la reducción de peso y la resolución de comorbilidades comparando dos técnicas quirúrgicas, baipás gástrico en Y de Roux y manga gástrica. Métodos. Estudio descriptivo de tipo analítico que incluyó pacientes con obesidad grados II y III. Se analizaron variables demográficas y perioperatorias, y las comorbilidades asociadas a la obesidad. La reducción del peso se evaluó con el porcentaje de pérdida del exceso de peso. Se realizó un análisis descriptivo univariado, usando medianas, rangos intercuartílicos, frecuencias y proporciones. Se usaron las pruebas de U de Mann-Whitney y Chi cuadrado para el análisis de grupos. Un valor de p<0,05 fue considerado estadísticamente significativo. Resultados. Fueron incluidos 201 pacientes. La mediana del porcentaje de pérdida del exceso de peso a 18 meses fue de 77,4 % para el grupo de baipás gástrico en Y de Roux vs 69,5 % para el grupo de manga gástrica (p=0,14). La mayoría de los pacientes presentaron resolución o mejoría de la hipertensión arterial (76 %), diabetes mellitus (80 %), dislipidemia (73 %), apnea del sueño (79 %) y artropatías (94 %), sin diferencia significativa según la técnica quirúrgica empleada. La tasa de complicaciones mayores fue del 1,9 %. No se presentó mortalidad. La mediana de seguimiento fue 28 meses. Conclusión. El baipás gástrico en Y de Roux y la manga gástrica son procedimientos muy seguros y efectivos para la reducción del exceso de peso y la resolución de las comorbilidades asociadas a la obesidad

Introduction. Bariatric surgery is a valid strategy of treatment for severe obesity. The aim of this study is to evaluate weight loss and resolution of comorbidities comparing two procedures, Roux-en-Y gastric bypass and sleeve gastrectomy. Methods. Descriptive study of analytical type that included patients with obesity grades II and III. Demographic and perioperative variables were analyzed. The weight reduction was evaluated among others with the percentage of excess of body weight loss. Comorbidities associated with obesity were also analyzed. A univariate descriptive analysis was performed, using medians, interquartile ranges, frequencies, and proportions. The Mann-Whitney U and Chi squared tests were used for analysis of groups. A value of p <0.05 was considered statistically significant. Median follow-up was 28 months. Results. A total of 201 patients were included in the analysis. The median percentage of excess of body weight loss at 18 months was 77.4% for Roux-en-Y gastric bypass group vs 69.5% for sleeve gastrectomy group (p=0.14). The majority of patients presented resolution or improvement of hypertension (76%), diabetes mellitus (80%), dyslipidemia (73%), sleep apnea (79%), and arthropathy (94%), without significant differences according to the surgical technique used. Major complication rate was 1.9%. There was not mortality. The median follow-up was 28 months. Conclusion. Roux-en-Y gastric bypass and sleeve gastrectomy are both very safe and effective procedures for excess weight reduction and resolution of comorbidities associated with obesity

Obesity and female sexual dysfunctions: A systematic review of prevalence with meta-analysis.

Obesity represents a major global health challenge. Female sexual dysfunctions have a negative impact on quality of life and overall health balance. A higher rate of female sexual dysfunctions in obese women has been suggested. This systematic review summarized the literature on female sexual dysfunction prevalence in obese women. The review was registered (Open Science Framework OSF.IO/7CG95) and a literature search without language restrictions was conducted in PubMed, Embase and Web of Science, from January 1990 to December 2021. Cross-sectional and intervention studies were included, the latter if they provided female sexual dysfunction rate data in obese women prior to the intervention. For inclusion, studies should have used the female sexual function index or its simplified version. Study quality was assessed to evaluate if female sexual function index was properly applied using six items. Rates of female sexual dysfunctions examining for differences between obese vs class III obese and high vs low quality subgroups were summarized. Random effects meta-analysis was performed, calculating 95% confidence intervals (CI) and examining heterogeneity with I2 statistic. Publication bias was evaluated with funnel plot. There were 15 relevant studies (1720 women participants in total with 153 obese and 1567 class III obese women). Of these, 8 (53.3%) studies complied with >4 quality items. Overall prevalence of female sexual dysfunctions was 62% (95% CI 55-68%; I2 85.5%). Among obese women the prevalence was 69% (95% CI 55-80%; I2 73.8%) vs 59% (95% CI 52-66%; I2 87.5%) among those class III obese (subgroup difference p=0.15). Among high quality studies the prevalence was 54% (95% CI 50-60%; I2 46.8%) vs 72% (95% CI 61-81%; I2 88.0%) among low quality studies (subgroup difference p=0.002). There was no funnel asymmetry. We interpreted that the rate of sexual dysfunctions is high in obese and class III obese women. Obesity should be regarded as a risk factor for female sexual dysfunctions.

Cirugía laparoscópica en pacientes con obesidad mórbida y cáncer de endometrio

Introducción: La cirugía, en pacientes con obesidad mórbida, como tratamiento del cáncer ginecológico supone un reto para el cirujano y el anestesiólogo, pues se asocia a un incremento de las complicaciones intra y posoperatorias. Objetivo: Describir los principales resultados con la cirugía laparoscópica, en pacientes con obesidad mórbida y adenocarcinoma de endometrio, tratadas en el Instituto Nacional de Oncología y Radiobiología (INOR) de la Habana, Cuba, en el período comprendido enero de 2019 a marzo de 2020. Método: Se realizó un estudio descriptivo, observacional y transversal, en 22 pacientes con índice de masa corporal mayor de 40 kg/m2 y diagnóstico de adenocarcinoma de endometrio, que fueron sometidas a cirugía laparoscópica. El dato primario fue obtenido a través de las historias clínicas, con los que se confeccionó una base de datos en una hoja de Microsoft Excel para sintetizar toda la información. Resultados: Predominó la edad entre 61 a 70 años. El adenocarcinoma endometrioide fue el más frecuente con el 77,27 %. El grado de diferenciación fue el bien diferenciado, infiltrando menos del 50 % del miometrio. El estadiamiento quirúrgico predominante fue el IA (72,72 %). El sangrado transoperatorio fue de 78,9 ± 5,7ml (rango 10 y 200 ml), la media del acto operatorio de 82 min (rango 75-132 min), y la estadía hospitalaria de menos de 24 horas (90,90 %). La conversión quirúrgica se realizó en el 4,54 % de los casos. Conclusiones: Las pacientes con obesidad mórbida pueden beneficiarse del abordaje laparoscópico para el tratamiento y la estatificación quirúrgica laparoscópica del carcinoma endometrial, lo que disminuye la morbilidad y la estadía hospitalaria.

Introduction: Surgery in morbidly obese patients as a treatment for gynecologic cancer is a challenge for surgeons and anesthesiologists, since it is associated with the processes of increasing intraoperative and postoperative complications. Objective: To describe the main results gained with the use of laparoscopic surgery in patients with morbid obesity and endometrial adenocarcinoma treated at the Instituto Nacional de Oncología y Radiobiología (INOR) of Havana, Cuba, from January 2019 to March 2020. Method: A descriptive, observational, cross-sectional study was carried out in 22 patients, with body mass index more than 40 kg/m2 and diagnosis of endometrial adenocarcinoma, who underwent laparoscopic surgery. The primary data was obtained from the medical records, which were used to create a database in a Microsoft Excel spreadsheet to synthesize all the information. Results: The predominant age group was between 61 and 70 years old. Endometrial adenocarcinoma was the most frequent cancer (77.27%). The degree of differentiation was well differentiated, infiltrating less than 50 % of the myometrium. The predominant surgical staging was IA (72.72%). Transoperative bleeding was 78.9 ± 5.7 ml (range between 10 and 200 ml), mean operative time was 82 min (range 75-132 min), and hospital stay was less than 24 hours (90.90%). Surgical conversion was performed in 4.54% of cases. Conclusions: Morbidly obese patients may benefit from the laparoscopic approach for the treatment and laparoscopic surgical staging of endometrial carcinoma, which decreases morbidity and hospital stay.

Introdução: A cirurgia, em pacientes com obesidade mórbida, como tratamento para o câncer ginecológico é um desafio para o cirurgião e para o anestesiologista, pois está associada ao aumento de complicações intra e pós-operatórias. Objetivo: Descrever os principais resultados da cirurgia laparoscópica, em pacientes com obesidade mórbida e adenocarcinoma endometrial, tratados no Instituto Nacional de Oncología y Radiobiología (INOR) em Havana, Cuba, no período de janeiro de 2019 a março de 2020. Método: A estudo descritivo, observacional e transversal realizado em 22 pacientes com índice de massa corporal superior a 40 kg/m2 e diagnóstico de adenocarcinoma de endométrio, submetidas à cirurgia laparoscópica. Os dados primários foram obtidos por meio dos prontuários, com os quais foi criado um banco de dados em uma planilha do Microsoft Excel para sintetizar todas as informações. Resultados: Predominou a idade entre 61 a 70 anos. O adenocarcinoma endometrioide foi o mais frequente com 77,27%. O grau de diferenciação foi bem diferenciado, infiltrando menos de 50% do miométrio. O estadiamento cirúrgico predominante foi IA (72,72%). O sangramento transoperatório foi de 78,9 ± 5,7 ml (variação de 10 e 200 ml), a média do ato cirúrgico foi de 82 min (variação de 75-132 min) e o tempo de internação foi inferior a 24 horas (90,90%). A conversão cirúrgica foi realizada em 4,54% dos casos. Conclusões: Pacientes com obesidade mórbida podem se beneficiar da abordagem laparoscópica para o tratamento e estadiamento cirúrgico laparoscópico do carcinoma endometrial, o que diminui a morbidade e o tempo de internação.

Factores de riesgo asociados a la pérdida insuficiente o ganancia significativa de peso en pacientes sometidos a cirugía bariátrica / Risk factors associated with insufficient weight loss or significant weight gain in patients undergone bariatric surgery

Introducción. La cirugía bariátrica es efectiva para inducir una rápida pérdida del exceso de peso, pero existen dudas sobre la duración de este efecto a largo plazo. Este estudio buscaba identificar la proporción de pacientes operados que presentaron una pérdida insuficiente o una ganancia significativa de peso y los posibles factores relacionados. Métodos. Estudio de cohorte retrospectivo en pacientes adultos sometidos a cirugía bariátrica. Se describieron variables demográficas y clínicas. Se realizó un análisis multivariado para identificar factores relacionados con un peso fuera de metas posterior a la cirugía. Resultados. Se incluyeron 187 pacientes, 117 con baipás gástrico y 70 con manga gástrica. La mediana de índice de masa corporal preoperatorio fue 41,3 kg/m2 y postoperatorio de 28,8 kg/m2. El 94,7 % de los pacientes en ambos grupos logró una adecuada pérdida del exceso de peso. La ganancia de peso mayor del 20 % se presentó en el 43,5 % de los pacientes, siendo mayor en el grupo de manga gástrica (p<0,004). Los factores independientes para ganancia de peso fueron el sexo masculino (OR 5,5), cirugía tipo manga gástrica (OR 3,4), síndrome de apnea del sueño (OR 2,9) y enfermedad mental medicada (OR 2,8). Conclusión. La cirugía bariátrica produce una pérdida del exceso de peso suficiente en casi la totalidad de los pacientes, pero un buen número recuperan peso luego de 3 años. Los principales factores asociados a ganancia de peso son el sexo masculino y la cirugía tipo manga gástrica

Introduction. Bariatric surgery is highly effective in inducing rapid excess body weight loss but there are doubts about its effect on long-term. This study seeks to identify the number of patients that underwent bariatric surgery who present insufficient weight loss or significant weight gain and the possible related factors. Methods. Retrospective cohort study of adult patients who underwent bariatric surgery. Demographic and clinical variables are described. A multivariate analysis was performed to identify factors related to patient weight outside the set goals postoperatively. Results. 187 patients were included (117 gastric bypass, 70 gastric sleeve). The median preoperative body mass index was 41m/kg2 and 28.8m/kg2 postoperatively. 94.7% of the patients in both groups achieved adequate excess body weight loss. Weight gain (>20%) occurred in 43.5% of the patients, with the probability being higher in the gastric sleeve group (p<0.004). Independent factors for weight gain were male gender (OR 5.5), gastric sleeve surgery (OR 3.4), sleep apnea syndrome (OR 2.9), and mental illness under treatment (OR 2.8). Conclusions. Bariatric surgery produces sufficient loss of excess weight in almost all patients, but a good number of them regain weight after 3 years. The main factors associated with weight gain are male gender and gastric sleeve surgery

Recommendations for the diagnosis and treatment of hypoglycaemia after bariatric surgery.

Postprandial hyperinsulinaemic hypoglycaemia is a common complication of bariatric surgery. Although in general its evolution is mild and self-limited, it can lead to neuroglycopaenia and compromise the patient's safety and quality of life. The aim of this document is to offer some recommendations to facilitate the clinical care of these complex patients, reviewing the aetiopathogenesis, its diagnosis and treatment that, sequentially, will include dietary and pharmacological measures and surgery in refractory cases. In the absence of high-quality studies, the diagnostic and therapeutic approach proposed is based on the consensus of experts of the Grupo de Obesidad de la Sociedad Española de Endocrinología y Nutrición [Obesity Group of the Spanish Society of Endocrinology and Nutrition], GOSEEN. Those undergoing bariatric surgery should be informed of the possibility of developing this complication.

Resultados neonatales adversos según grados de obesidad pregestacional en un hospital público del sur de Perú, 2010 a 2019

Introducción: La obesidad materna, creciente problema de salud pública mundial, se relaciona con morbimortalidad neonatal. El objetivo fue determinar los resultados neonatales adversos según los grados de obesidad pregestacional. Material y método: Estudio analítico, de cohorte retrospectiva, en gestantes de embarazo único, de parto atendido en el hospital Hipólito Unanue de Tacna Perú, durante 2010 a 2019, con recién nacido vivo, los casos fueron 5935 madres con índice de masa corporal pregestacional de 30 Kg/m2 a más, agrupadas en grado I (IMC 30-34,9 Kg/m2), II (IMC 35-39,9 Kg/m2) y III (IMC>40 Kg/m2), los controles madres con IMC de 18-24,9 Kg/m2. Se excluyeron gestantes con diabetes mellitus, preeclampsia, eclampsia y anomalías congénitas. Se utilizó Riesgo Relativo (RR) crudo y ajustado por edad materna, escolaridad y paridad, con intervalo de confianza al 95%. Resultados: La frecuencia de obesidad pregestacional fue 14,3% grado I, 3,8% grado II y 1% grado III. Los resultados neonatales que se asociaron fueron: peso al nacer >4000 gramos, para obesidad grado I (RRa: 1,9; IC95%:1,7-2,0), grado II (RRa: 2,0; IC95%:1,8-2,3) y grado III (RRa: 2,1; IC95%:1,7-2,5); grande para la edad gestacional para grado I (RRa: 1,6; IC95%: 1,4-1,7), grado II (RRa: 1,7; IC95%: 1,6-1,9) y grado III (RRa: 1,8; IC95%: 1,4-2,1). Conclusiones: Existe mayor riesgo de macrosomía fetal y grande para la edad gestacional a mayor grado de obesidad pregestacional materna.

Background: Maternal obesity, a growing global public health problem, is related to neonatal morbidity and mortality. The objective was to determine adverse neonatal outcomes according to degrees of pregestational obesity. Material and method: Analytical study, retrospective cohort, in pregnant women with a single pregnancy, delivery attended at the Hipolito Unanue hospital in Tacna, Peru, during 2010 to 2019, with live newborns, the cases were 5935 mothers with pre-pregnancy body mass index from 30 Kg/m2 to more, grouped in grade I (BMI 30-34.9 Kg/m2), II (BMI 35-39.9 Kg/m2) and III (BMI>40 Kg/m2), the control mothers with a BMI of 18-24.9 Kg/m2. Pregnant women with diabetes mellitus, preeclampsia, eclampsia and congenital anomalies were excluded. Crude Relative Risk (RR) was used, adjusted for maternal age, schooling and parity, with a 95% confidence interval. Results: The frequency of pre-pregnancy obesity was 14.3% grade I, 3.8% grade II and 1% grade III. The associated neonatal outcomes were: birth weight >4000 grams, for grade I obesity (RRa: 1.9; 95% CI: 1.7-2.0), grade II (RRa: 2.0; 95% CI: 1.8-2.3) and grade III (RRa: 2.1; CI95%: 1.7-2.5); large for gestational age for grade I (RRa: 1.6; 95% CI: 1.4-1.7), grade II (RRa: 1.7; 95% CI: 1.6-1.9) and grade III (RRa: 1.8; CI95%: 1.4-2.1). Conclusions: There is an increased risk of fetal macrosomia and large for gestational age with a higher degree of maternal pregestational obesity.

Bariatric surgery and non-alcoholic fatty liver disease / Cirugía bariátrica e hígado graso no alcohólico

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease that may lead to cirrhosis and hepatocellular carcinoma; its close relationship with obesity and the metabolic syndrome involves an increasing prevalence. Invasive liver biopsy is the gold standard diagnosis technique for NAFLD but entails risks. Therefore, transient elastography, a non-invasive technique with high reliability, is frequently used in clinical practice. Bariatric surgery is the only effective treatment for long-term weight loss and obesity-related metabolic conditions improvement. Although studies report encouraging results of bariatric surgery as a valuable therapy for NAFLD, guidelines for its use in NAFLD are ambiguous. Indeed, the mechanisms driving this improvement are largely unknown, but likely involve weight loss-dependent and independent factors including anatomic and hormonal changes. This review aims to update the relationship between NAFLD and bariatric surgery, focusing on the indications for surgery and the mechanisms implied in NAFLD improvement. (AU)

El hígado graso no alcohólico (HGNA) es una enfermedad crónica que puede conducir a cirrosis y hepatocarcinoma; su relación con la obesidad y el síndrome metabólico supone un aumento en su prevalencia. La biopsia hepática es la prueba diagnóstica de elección, pero implica riesgos. En consecuencia, la elastografía hepática, una técnica no invasiva con una alta fiabilidad, es utilizada frecuentemente en la práctica clínica. La cirugía bariátrica es el único tratamiento eficaz para la pérdida de peso y la mejoría de las comorbilidades a largo plazo. Aunque los estudios demuestran que la cirugía bariátrica es efectiva para el tratamiento del HGNA, la mayoría de los mecanismos implicados en esta mejoría se desconocen. De hecho, las guías clínicas son ambiguas en cuanto a su indicación. Esta revisión tiene como objetivo actualizar la relación entre el HGNA y la cirugía bariátrica, centrándose en las indicaciones de la cirugía y los mecanismos implicados en la mejoría del HGNA. (AU)

Características de adultos com obesidade grave em tratamento ambulatorial no Rio de Janeiro e fatores associados à perda de peso / Characteristics of adults with severe obesity in clinical treatment in Rio de Janeiro and factors associated with weight loss / Características de adultos con obesidad severa en tratamiento clínico en Rio de Janeiro y factores asociados a la pérdida de peso

Resumo Introdução O tratamento da obesidade grave é pouco estudado no Sistema Único de Saúde (SUS). Objetivo: Descrever clientela, atendimento e fatores associados à perda de peso em Centros de Referência em Obesidade (CRO), na cidade do Rio de Janeiro. Método Coorte retrospectiva baseada em registros de prontuários de 317 indivíduos com obesidade grave atendidos em três CRO-RJ entre 2011 e 2016. Foram descritas frequências e estimados riscos relativos com IC 95% para perda de ≥ 5% do peso inicial aos 6 e 12 meses de tratamento. Resultados Predominaram mulheres (76,3%), negros (69,5%), com média de 44,6 anos (DP 11,9), tratamento prévio para obesidade (62,1%), história familiar de obesidade (42,6%) e 2 ou mais comorbidades (52%). A mediana do IMC inicial foi de 51,5 kg/m2, e a do tempo de tratamento, 10 meses. Somente 14,8% perderam ≥ 5% do peso inicial após 12 meses de tratamento, sendo o risco relativo de perda de peso 78% maior entre indivíduos brancos. Predominaram tratamento dietético e mudanças de hábitos de vida, com baixo uso de medicamentos antiobesidade (14%) e cirurgia bariátrica (3%, sendo 1% no SUS). Conclusão Os resultados do tratamento sugerem necessidade de readequar práticas terapêuticas às indicadas para indivíduos com superobesidade, inclusive maior acesso à cirurgia bariátrica.

Abstract Background There are few studies on severe obesity in the Brazilian Unified Health System (SUS). Objective To describe patients, treatment approaches and factors associated with weight loss at the Obesity Reference Centers (CRO), in the city of Rio de Janeiro. Method Retrospective cohort study based on medical records of 317 patients with severe obesity admitted to three CRO-RJ, between 2011 and 2016. Frequencies were described and relative risks with 95% CI of ≥ 5% loss of body weight at 6 and 12 months of treatment were estimated. Results Patients were mainly black (69.5%), women (76.3%), mean age 44.6 years (SD 11.9), reporting ≥ 2 comorbidities (52%), previous treatment (62.1%) and family history of obesity (42.6%). The initial mean BMI was 51.5 kg/m2; average treatment time was 10 months. 14.8% lost ≥ 5% of the initial weight after 12 months of treatment and the relative risk of weight loss was 78% higher among white patients. Approaches based on diet and changes in lifestyle predominated. 14% used anti-obesity drugs and 3% underwent bariatric surgery (1% in the SUS). Conclusion Treatment results suggest the need to adjust management to follow treatment guidelines for superobesity, including bariatric surgery.

Resumen Introducción El tratamiento de la obesidad severa está poco estudiado en el SUS. Objetivo Describir la clientela, el manejo y los factores asociados con la pérdida de peso en los Centros de Referencia para la Obesidad (CRO), en la ciudad de Río de Janeiro. Método Cohorte retrospectiva basada en registros médicos de 317 individuos con obesidad severa tratados en tres CRO-RJ entre 2011 y 2016. Se describieron las frecuencias y estimaron riesgos relativos con un IC del 95% para la pérdida de ≥ 5% del peso inicial a los 6 y 12 meses de tratamiento. Resultados Predominaron las mujeres (76.3%), negros (69.5%), con una media de 44.6 años (DE 11.9), tratamiento previo (62.1%), antecedentes familiares de obesidad (42.6%) y dos o más comorbilidades (52.0%). La mediana del IMC inicial fue de 51.5 kg/m2 y el tiempo de tratamiento fue de 10 meses. Solo el 14.8% perdió ≥ 5% de su peso inicial después de 12 meses de tratamiento, con un riesgo de pérdida de peso 78% mayor entre los individuos blancos. Predominaron el tratamiento dietético y los cambios en los hábitos de estilo de vida, con un bajo uso de medicamentos contra la obesidad (14%) y cirugía bariátrica (3%, 1% en SUS). Conclusión Los resultados del tratamiento sugieren la necesidad de reajustar las prácticas terapéuticas a las indicadas en la superobesidad, incluido un mayor acceso a la cirugía bariátrica.

Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in morbid obesity (MO). A considerable proportion of patients with MO have non-alcoholic steatohepatitis (NASH). Liver biopsy (LB) is the only procedure that reliably differentiates NASH from other stages of NAFLD, but its invasive nature prevents it from being generalisable. Hence, non-invasive assessment is critical in this group of patients. OBJECTIVES: To report NAFLD/NASH prevalence in a cohort of patients with MO and to identify predictors of NASH. METHODS: Fifty-two consecutive patients subjected to bariatric surgery in a University hospital in Spain underwent LB. Anthropometric, clinical and biochemical variables were registered. According of the results of the LB, individuals were classified by whether they had NASH or not. Multiple logistic regression analysis was performed to identify independent factors associated with NASH. RESULTS: NAFLD was reported in 94.2% of the patients, simple steatosis was present in 51.92% and NASH in 42.31%. Meanwhile, 17.3% of patients exhibited significant fibrosis (≥F2). HIGHT score for NASH risk was established using five independent predictors: systemic Hypertension, Insulin resistance, Gamma-glutamyl transferase, High density lipoprotein cholesterol and alanine Transaminase. This score ranges from 0 to 7 and was used to predict NASH in our cohort (area under the receiver operator characteristic curve 0.846). A score of 4 or greater implied high risk (sensitivity 77.3%, specificity 73.3%, positive predictive value 68%, negative predictive value 81.5%, accuracy 75%). CONCLUSIONS: NAFLD is practically a constant in MO with a considerable proportion of patients presenting NASH. The combination of five independent predictors in a scoring system may help the clinician optimise the selection of patients with MO for LB.

Medium-term complications in patients undergoing gastric bypass.

OBJECTIVE: To present our experience in the clinical follow-up of patients undergoing a gastric bypass. METHOD: Description of six cases under follow-up by our unit after undergoing a gastric bypass at another private centre. RESULTS: The 6 patients presented complications, the most notable being the death of one patient due to severe malnutrition and the need for revision surgery in another for the same reason, destabilisation of type 1 diabetes mellitus in another patient and fat-soluble vitamin deficiency in all of them. CONCLUSIONS: There are few publications that support the safety of gastric bypass as a treatment for obesity. In our experience, it is a technique associated with a high rate of serious complications. As it is a technique that is not yet standardised, we consider that these cases should be operated on in centres where there is a multidisciplinary team with expertise in the management of possible complications, with close follow-up by surgeons and endocrinologists.

Factores desencadenantes actuales de la obesidad / Obesity and its consequences today

Objetivo: Analizar la obesidad y sus consecuencias como problema de salud pública en la actualidad. Método: Revisión sistemática de artículos publicados en PubMed. Resultados: Se escrutaron 17 artículos que presentan información relevante al tema planteado. Conclusión: Se han identificado varios síndromes específicos, siendo la obesidad el síntoma principal. Estas raras causas de obesidad representan menos del 1% de los casos de obesidad en niños en el entorno de la atención terciaria. La obesidad también es un componente de síndromes genéticos relativamente comunes, incluido el síndrome de Down.

Objective: To analyze obesity and its consequences as a current public health problem. Method: Systematic review of articles published in PubMed. Results: Seventeen articles were scrutinized and presented information relevant to the topic in question. Conclusion: Several specific syndromes have been identified, with obesity being the main symptom. These rare causes of obesity account for less than 1% of obesity cases in children in the tertiary care setting. Obesity is also a component of relatively common genetic syndromes, including Down syndrome.

Factores de riesgo litogénicos en obesos mórbidos en el preoperatorio de cirugía bariátrica

Resumen: Introducción: La obesidad mórbida es un factor de riesgo para litiasis renal. La cirugía bariátrica, logra buenos resultados metabólicos, pudiendo generar un aumento del riesgo de litiasis renal. Objetivo. Estudiar los factores de riesgo litogénicos en pacientes obesos en el pre operatorio de cirugía bariátrica. Metodología: Estudio descriptivo, transversal. Se incluyeron pacientes del Programa de Obesidad y Cirugía Bariátrica, de febrero de 2019 a marzo de 2020. Resultados: Se analizaron 68 pacientes, 83,3% mujeres, mediana de edad 46 (37-52) años. La mediana del IMC fue de 46 (43-53) kg/m² con un rango de 35 a 70 kg/m². De los participantes 29 (43%) eran súper-obesos (IMC>50kg/m2), 31 (48%) presentaban síndrome metabólico, 19 (28,7%) eran diabéticos, 39 (59%) eran hipertensos. La mediana del clearence de creatinina medido fue de 136,5 (100,5-162,5) ml/min, 41 (60%) pacientes fue mayor a 120 ml/min. En 16 (23%) pacientes se constató el antecedente de manifestación clínica - ecográfica de litiasis. Todos los pacientes estaban asintomáticos al momento del estudio. Encontramos al menos 1 factor litogénico en 97% pacientes y 2 en el 71%. El 60,6% tenían hiperparatiroidismo, el 63% con hipovitaminosis D ( 100 mmol/24hs, 60,3% hiperuricosuria, 48,5% tenían hipocitraturia, 42,6% hiperoxaluria, 25% hipercalciuria y 79,4% con hiperamoniuria. No se evidencio diferencias en las variables litogénicas, entre pacientes con antecedentes de litiasis y sin antecedentes, en pacientes obesos y superobesos, ni al comparar pacientes diabéticos y con síndrome metabólico vs pacientes sin estas alteraciones. Discusión y conclusiones: En nuestro estudio la alta prevalencia de factores de riesgo litogénicos, apoya el vínculo entre obesidad y la patología litiásica renal. Es aconsejable la evaluación clínica específica y la realización de un estudio litogénico previo a la cirugía bariátrica, incidiendo su resultado en la elección de la técnica quirúrgica.

Abstract: Introduction: Morbid obesity is a risk factor for kidney stones. Bariatric surgery achieves good metabolic results, and can generate an increased risk of kidney stones. Target. To study the lithogenic risk factors in obese patients in the preoperative period of bariatric surgery. Methodology: Descriptive, cross-sectional study. Patients from the Obesity and Bariatric Surgery Program were included, from February 2019 to March 2020. Results: 68 patients were analyzed, 83.3% women, median age 46 (37-52) years. The median BMI was 46 (43-53) kg/m² with a range of 35 to 70 kg/m². Of the participants, 29 (43%) were super-obese (BMI>50kg/m2), 31 (48%) had metabolic syndrome, 19 (28.7%) were diabetic, and 39 (59%) were hypertensive. The median creatinine clearance measured was 136.5 (100.5-162.5) ml/min, 41 (60%) patients were greater than 120 ml/min. In 16 (23%) patients, a history of clinical-ultrasound manifestation of lithiasis was confirmed. All patients were asymptomatic at the time of the study. We found at least 1 lithogenic factor in 97% patients and 2 in 71%. 60.6% had hyperparathyroidism, 63% with hypovitaminosis D (100 mmol/24h, 60.3% had hyperuricosuria, 48.5% had hypocitraturia, 42.6% hyperoxaluria, 25% hypercalciuria and 79.4% with hyperammoniuria. No differences were found in the lithogenic variables, between patients with a history of lithiasis and without, in obese and super obese patients, or when comparing diabetic patients and patients with metabolic syndrome vs patients without these alterations. Discussion and Conclusions: In our study, the high prevalence of lithogenic risk factors supports the link between obesity and kidney stone disease. It is advisable to carry out a specific clinical evaluation and a lithogenic study prior to bariatric surgery, with its result affecting the choice of surgical technique.

Resumo: Introdução: A obesidade mórbida é um fator de risco para cálculos renais. A cirurgia bariátrica alcança bons resultados metabólicos, podendo gerar um risco aumentado de cálculos renais. Alvo. Estudar os fatores de risco litogênicos em pacientes obesos no pré-operatório de cirurgia bariátrica. Metodologia: Estudo descritivo, transversal. Foram incluídos pacientes do Programa de Obesidade e Cirurgia Bariátrica, no período de fevereiro de 2019 a março de 2020. Resultados: Foram analisados ​​68 pacientes, 83,3% mulheres, idade mediana de 46 (37-52) anos. A mediana do IMC foi de 46 (43-53) kg/m² com variação de 35 a 70 kg/m². Dos participantes, 29 (43%) eram superobesos (IMC>50kg/m2), 31 (48%) tinham síndrome metabólica, 19 (28,7%) eram diabéticos e 39 (59%) eram hipertensos. A mediana da depuração de creatinina medida foi de 136,5 (100,5-162,5) ml/min, 41 (60%) pacientes foram maiores que 120 ml/min. Em 16 (23%) pacientes foi confirmada história de manifestação clínico-ultrassonográfica de litíase. Todos os pacientes estavam assintomáticos no momento do estudo. Encontramos pelo menos 1 fator litogênico em 97% dos pacientes e 2 em 71%. 60,6% tinham hiperparatireoidismo, 63% com hipovitaminose D (100 mmol/24h, 60,3% tinham hiperuricosúria, 48,5% tinham hipocitratúria, 42,6% hiperoxalúria, 25% hipercalciúria e 79,4% com hiperamonúria. Não foram encontradas diferenças nas variáveis litogênicas, entre pacientes com e sem história de litíase, em pacientes obesos e superobesos, ou ao comparar pacientes diabéticos e pacientes com síndrome metabólica versus pacientes sem essas alterações. Discussão e Conclusões: Em nosso estudo, a alta prevalência de fatores de risco litogênicos suporta a ligação entre obesidade e patologia de cálculos renais. Aconselha-se a realização de avaliação clínica específica e estudo litogênico prévio à cirurgia bariátrica, cujo resultado interfere na escolha da técnica cirúrgica.

Efecto selectivo de bypass gástrico laparoscópico en Y de Roux sobre el metabolismo lipídico / Selective effect of laparoscopic Roux-en-Y gastric bypass on lipid metabolism

INTRODUCCIÓN: La cirugía bariátrica (CB) ha mostrado reducir la morbilidad y mortalidad cardiovascular en obesidad mórbida. La CB ha mejorado la dislipemia del paciente insulinorresistente (IR). El objetivo de nuestro trabajo fue evaluar si existe diferencia en el perfil lipídico entre la técnica de bypass gástrico laparoscópico en Y de Roux (BGYRL) vs. la técnica de la gastrectomía tubular laparoscópica (GTL) a 18 meses de seguimiento. MÉTODOS: Estudio observacional, abierto, prospectivo, de pacientes con obesidad mórbida sometidos que realizaron a cirugía bariátrica a 18 meses seguimiento. Se realizaron análisis antropométricos, composición corporal, gasto energético de reposo, de glucosa, insulina, hemoglobina glucosilada (HbA1c), lipoproteínas de baja densidad (LDL), lipoproteínas de alta densidad (HDL), triglicéridos (TG) y colesterol total (CT). RESULTADOS: No se encontraron diferencias basales de la proporción de pacientes con hipertensión arterial, diabetes de tipo 2, esteatosis y de sexo entre los grupos de BGYRL (91) vs. GTL (77). Se observo reducción de TG a los seis meses a favor de BGYRL vs. GTL: 108,60± 34,86 vs. 124,59±44,58; p = 0,044), en cambio se encontró disminución tanto de niveles de LDL a los 12 y 18 meses a favor del grupo BGYRL vs. GTL: 96,23±24,33 vs. 107,83±28,88, p = 0,025; 90,98±20,62 vs. 106,22±31,48, p = 0,003; la disminución de CT se observó solo a los 18 meses a favor del grupo BGYRL vs. GTL: 171,39±25,058 vs. 186,89±31,81, p = 0,005.ConclusiónEl BGYRL ha mostrado ser más eficaz para reducir LDL y CT en comparación con GTL, lo cual otorga un beneficio adicional del BGYRL en relación al perfil lipídico del paciente.

INTRODUCTION: Bariatric surgery (BS) has shown to reduce cardiovascular morbidity and mortality in obesity. The BS has improved the dyslipidemia of the insulin resistant patient, our objective was to evaluate if there was a difference in the lipid profile between the laparoscopic roux-en-Y gastric bypass (RYGB) technique vs. the sleeve gastrectomy (SG) technique at 18 months of follow-up. METHODS: An observational, open, prospective study of morbidly obese patients who underwent bariatric surgery at 18-month follow-up. Anthropometric analysis, body composition, energy expenditure at rest, glucose, insulin, HbA1c, LDL, HDL, TG and CT were performed. RESULTS: Absence baseline differences were found in the proportion of patients with hypertension, diabetes, steatosis, and sex between the RYGB vs SG groups. A reduction of TG was observed at 6 months in favor of RYGB vs SG: 108.60±34.86 vs. 124.59±44.58, P = 0.044), however, a decrease in both LDL levels was found at 12 and 18 months in favor of the RYGB vs. SG group: 96.23±24.33 vs. 107.83±28.88, P = 0.025; 90.98±20.62 vs 106.22±31.48, P = 0.003; the decrease in CT was observed only at 18 months in favor of the RYGB vs. SG group: 171.39±25.058 vs. 186.89±31.81, P = 0.005. CONCLUSIONS: RYBG has shown to be more effective in reducing LDL and CT levels compared to SG, which provides an additional benefit of RYGB in relation to the lipid profile of the patient.

Bariatric surgery and non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease that may lead to cirrhosis and hepatocellular carcinoma; its close relationship with obesity and the metabolic syndrome involves an increasing prevalence. Invasive liver biopsy is the gold standard diagnosis technique for NAFLD but entails risks. Therefore, transient elastography, a non-invasive technique with high reliability, is frequently used in clinical practice. Bariatric surgery is the only effective treatment for long-term weight loss and obesity-related metabolic conditions improvement. Although studies report encouraging results of bariatric surgery as a valuable therapy for NAFLD, guidelines for its use in NAFLD are ambiguous. Indeed, the mechanisms driving this improvement are largely unknown, but likely involve weight loss-dependent and independent factors including anatomic and hormonal changes. This review aims to update the relationship between NAFLD and bariatric surgery, focusing on the indications for surgery and the mechanisms implied in NAFLD improvement.

Selective effect of laparoscopic Roux-en-Y gastric bypass on lipid metabolism. / Efecto selectivo de bypass gástrico laparoscópico en Y de Roux sobre el metabolismo lipídico.

INTRODUCTION: Bariatric surgery (BS) has shown to reduce cardiovascular morbidity and mortality in obesity. The BS has improved the dyslipidemia of the insulin resistant patient, our objective was to evaluate if there was a difference in the lipid profile between the laparoscopic roux-en-Y gastric bypass (RYGB) technique vs. the sleeve gastrectomy (SG) technique at 18 months of follow-up. METHODS: An observational, open, prospective study of morbidly obese patients who underwent bariatric surgery at 18-month follow-up. Anthropometric analysis, body composition, energy expenditure at rest, glucose, insulin, HbA1c, LDL, HDL, TG and CT were performed. RESULTS: Absence baseline differences were found in the proportion of patients with hypertension, diabetes, steatosis, and sex between the RYGB vs SG groups. A reduction of TG was observed at 6 months in favor of RYGB vs SG: 108.60±34.86 vs. 124.59±44.58, P = 0.044), however, a decrease in both LDL levels was found at 12 and 18 months in favor of the RYGB vs. SG group: 96.23±24.33 vs. 107.83±28.88, P = 0.025; 90.98±20.62 vs 106.22±31.48, P = 0.003; the decrease in CT was observed only at 18 months in favor of the RYGB vs. SG group: 171.39±25.058 vs. 186.89±31.81, P = 0.005. CONCLUSIóN: RYBG has shown to be more effective in reducing LDL and CT levels compared to SG, which provides an additional benefit of RYGB in relation to the lipid profile of the patient.

Incisión transversa infraumbilical en una embarazada con obesidad mórbida: reporte de un caso / Infraumbilical transverse incision in a pregnant woman with morbid obesity: A case report

Resumen ANTECEDENTES: El sobrepeso y la obesidad van en aumento, sobre todo en los países con bajos y medios ingresos. La obesidad en el embarazo aumenta el riesgo de complicaciones, incluida la infección del sitio quirúrgico. OBJETIVO: Documentar la aplicación de una técnica quirúrgica adaptada para disminuir la infección del sitio quirúrgico en la cesárea de una paciente con obesidad mórbida. CASO CLÍNICO: Paciente de 43 años, con 35 semanas de embarazo, con alrededor de 6 horas de percepción de disminución de los movimientos fetales y dolor abdominal, tipo contracción de moderada intensidad. Con diagnósticos de diabetes gestacional no compensada, amenaza de parto pretérmino, obesidad mórbida, añosa, preeclampsia con signos de severidad, síndrome de HELLP y alto riesgo obstétrico. Por estas características, se decidió que la incisión para la cesárea fuera transversa infraumbilical. CONCLUSIONES: La técnica de incisión aplicada en la paciente del caso evitó el contacto con el pliegue subpanicular y disminuyó las complicaciones quirúrgicas.

Abstract BACKGROUND: Overweight and obesity are increasing every day mainly in low- and middle-income countries. Obesity in pregnancy increases the risk of complications, including surgical site infection. OBJECTIVE: To document the application of a surgical technique adapted for cesarean delivery of a pregnant woman with morbid obesity in a hospital in Ecuador, carried out to reduce the infection of the surgical site. CLINICAL CASE: a 43-year-old pregnant patient who came to the hospital due to decreased fetal movements accompanied by contraction-type abdominal pain of moderate intensity. Based on the tests performed, a 35.1-week twin pregnancy + uncompensated gestational diabetes + threat of preterm birth + morbid obesity + elderly mother + pre-eclampsia with signs of severity + HELLP syndrome + high obstetric risk was diagnosed. Due to the characteristics of the patient, it was decided to perform an infraumbilical transverse incision. CONCLUSIONS: the technique used can be an effective alternative in obese patients to reduce the infection of the surgical site; Compliance with aseptic measures and preoperative antibiotic prophylaxis should also be taken into consideration.

Evaluation of quality of life, weight loss and evolution of comorbidities at 6 years after bariatric surgery.

INTRODUCTION: Morbid obesity is a disease with multiple comorbidities and considerably limits the quality of life and life expectancy. Bariatric surgery is an effective therapeutic alternative in these patients; it acts on the decrease and / or absorption of nutrients, achieving a significant weight loss which is maintained over time. The objective of the study is to determine the long-term results, in terms of efficacy, regarding weight loss, the resolution of comorbidities and improvement in the quality of life of our patients. MATERIAL AND METHODS: This was a retrospective study that comprised all patients consecutively undergoing laparoscopic bariatric surgery at our center over a 10 year period. In all patients, the anthropometric and clinical data were collected prior to surgery and in subsequent protocolized visits after surgery. At the end of the follow-up, a BAROS questionnaire was used that recorded weight loss, the resolution of comorbidities, complications and the quality of life test completed by the patients. RESULTS: 353 patients (303 GBPRY and 50 GV), 105 men and 248 women, with a mean age of 42.14 ± 10.16 years, BMI 48.63 kg / m2 and 68.5% had some comorbidity. The mean follow-up was 5.7 ± 2.6 years for 96.7% of the total number operated on. At the end of the follow-up the %EWL was 59.00 ± 19.50, %EBMIL 68.15 ± 22.94, the final BMI 32.65 ± 5.98 and 31.3% of the patients had %EWL ≤ 50. The resolution of comorbidities was as follows: 48.7% hypertension, 70.3% Type 2 Diabetes, 82.6% DLP and 71.6% SAHS. The result of the quality of life test was 1.51 ± 0.93, with 67.2% of patients reporting good or very good quality, with the highest score being for self-esteem, followed by physical condition, work and social activity, and the lowest being for sexual quality of life in that only 40.3% reported an improvement. The BAROS score was 4.35 ±â€¯2.06 with 84.7% of the patients in the good to excellent range, while 91.2% of all patients would undergo surgery again. CONCLUSIONS: Bariatric surgery is an effective technique for reducing weight, resolving comorbidities and improving the quality of life of patients with morbid obesity, mainly in its physical aspect. In our series, the percentage of follow-up and average time was within the range of established quality standards.

Calidad de vida, pérdida ponderal y evolución de las comorbilidades: estudio comparativo de gastrectomía vertical vs. bypass gástrico. Resultados preliminares / Quality of life, weight loss and evolution of comorbidities: comparative study of sleeve vs bypass. Preliminary results

Resumen Objetivo: Comparar los resultados obtenidos en calidad de vida, pérdida ponderal y resolución de comorbilidades al año, en pacientes con obesidad mórbida intervenidos de Gastrectomía vertical laparoscópica (GVL) o bypass gástrico en Y de Roux laparoscópico (BGYRL) en nuestro centro. Materiales y Método: Estudio observacional de una base de datos prospectiva. Las variables del estudio fueron IMC pre y posoperatorio, porcentaje de exceso de IMC perdido (PEIMCP), puntuación obtenida en los cuestionarios Gastrointestinal Quality of Life Index (GIQLI) y Bariatric Analysis and Reporting Outcomes System (BAROS) y la resolución de las comorbilidades. Resultados: De 60 pacientes: 37 fueron intervenidos de GVL y 23 de BGYRL. El IMC posoperatorio al año fue 29,9 ± 4 kg/m2 en BGYRL y 31,3 ± 5 kg/m2 en GVL. El PEIMCP fue de 74,5 ± 19,2% (BGYRL) y de 67,5 ± 23,1% (GVL). Con BAROS, se obtuvieron resultados buenos o superiores en el 87% (BGYRL) y en 83,8% (GVL). Con GIQLI se obtuvo una puntuación media de 108,3 ± 19 (BGYRL) y 109,8 ± 18,3 (GVL). No se observaron diferencias estadísticamente significativas entre ambos grupos en ninguna de las variables previas. En cuanto a la evolución de las comorbilidades, 50% de BGYRL y 53,8% de GVL presentaron resolución de todas las comorbilidades. Conclusiones: Ambas técnicas son eficaces en cuanto al PEIMCP, a la calidad de vida y al control de comorbilidades al año de la intervención. El BGYRL presenta mejores resultados en PEIMCP y BAROS, y la GVL presenta mejor puntación global y especifica de síntomas digestivos con GIQLI, sin ser diferencias estadísticamente significativas.

Aim: The purpose of our study was to compare the postoperative quality of life, weight loss and improvement of co-morbidities in laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG) patients one year after surgery. Materials and Method: Match pair analysis of the prospectively collected database of the 23 gastric bypass and 37 gastric sleeve patients operated on in our hospital was performed. Weight loss, quality of life and improvement of co-morbidities were measured at one year after surgery. The quality of life parameters were measured with two standard questionnaires: Gastrointestinal Quality of Life Index (GIQLI) and Bariatric Analysis and Reporting Outcomes System (BAROS). Results: After one year of follow-up the mean BMI was 29.9 ± 4 kg/m2 in LRYGB and 31.3 ± 5 kg/m2 in LSG. The percent excess BMI Loss (%EBMIL) was 74.5 ± 19.2% (LRYGB) and 67.5 ± 23.1% (LSG). A success score in BAROS was obtained in 87% (LRYGB) and 83.8% (LSG). The mean GIQLI score was 108.3 ± 19 (LRYGB) and 109.8 ± 18.3 (LSG). These results did not differ significantly. Remission of co-morbidities was similar in the BGYRL and LSG groups (50 vs 53.8%). Conclusions: Both types of surgery are effective in quality of life, co-morbidities and weight loss after one year of follow-up. The LRYGB produced better results in %EBMIL and BAROS, and the LSG produced better results in GIQLI (overall and digestive symptoms). These results did not differ significantly.

Protocolo de Manejo de Cirugía Metabólica y Bariátrica del Hospital de Especialidades Carlos Andrade Marín / Management Protocol for Metabolic and Bariatric Surgery at the Carlos Andrade Marín Specialties Hospital

1. INTRODUCCIÓN. La obesidad mórbida es una enfermedad crónica multifactorial asociada a complicaciones físicas y psicológicas que empeoran la calidad de vida de los pacientes y disminuyen su esperanza de vida; es un problema sanitario de primera magnitud debido al incremento de esta patología en Ecuador y a las dificultades que entraña su prevención y tratamiento. La cirugía de la obesidad es compleja, no exenta de complicaciones, cuyo objetivo es reducir de manera significativa las comorbilidades asociadas y mejorar el bienestar de los pacientes, cuya técnica quirúrgica sea fácil de reproducir, con porcentajes de revisión bajos y que constituya un tratamiento eficaz y seguro para la obesidad clínicamente grave, con evidencia que demuestra reducción de la mortalidad por todas las causas, mejoría en la expectativa y calidad de vida de los pacientes1.

1. INTRODUCTION. Morbid obesity is a multifactorial chronic disease associated with physical and psychological complications that worsen the quality of life of patients and decrease their life expectancy; it is a health problem of the first magnitude due to the increase of this pathology in Ecuador and the difficulties involved in its prevention and treatment. Obesity surgery is complex, not exempt of complications, whose objective is to significantly reduce associated comorbidities and improve the well-being of patients, whose surgical technique is easy to reproduce, with low revision percentages and that constitutes an effective and safe treatment for clinically severe obesity, with evidence that shows a reduction in all-cause mortality, improvement in life expectancy and quality of life of patients1.